Author Interviews, Diabetes, Weight Research / 09.06.2026
ADA2026: Survodutide Achieves 16.6% Average Weight Loss with Targeted Visceral Fat Reduction in Phase 3 SYNCHRONIZE-1 Trial
Phase 3 SYNCHRONIZE-1 trial data shows survodutide achieves up to 16.6% average weight loss with targeted visceral fat reduction and...